Glioblastoma Multiforme Market
DelveInsight’s ‘Glioblastoma Multiforme (GBM) Market’ report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Glioblastoma Multiforme market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2017 to 2030. The report also covers current Glioblastoma Multiforme (GBM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Glioblastoma Multiforme (GBM) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population based on Histologic Classification of Glioblastoma Multiforme (GBM) Tumor in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Key Findings
This section provides glimpse of the Glioblastoma Multiforme (GBM) epidemiology in the 7MM.
- The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 28,259 in 2017. In case of Glioblastoma Multiforme patients in the United States, the diagnosed cases were 14,666 in 2017.
- The total diagnosed incident cases of Glioblastoma Multiforme patients were found to be maximum in males as compared to females in the 7 MM during the study period of 2017–2030.
- In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was found to be maximum in Germany with 2,876 cases followed by France with 2,683 cases in 2017. While, Spain accounted for the lowest diagnosed incident population of 1,403 in 2017.
- As per Delvelnsight’s analysis, Japan had 1,899 diagnosed incident cases of Glioblastoma Multiforme in 2017.
Glioblastoma Multiforme (GBM) Drug Chapters
The drug chapter segment of the Glioblastoma Multiforme (GBM) report encloses the detailed analysis of Glioblastoma Multiforme (GBM) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Glioblastoma Multiforme (GBM) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Glioblastoma Multiforme Marketed Drugs
Avastin: Genentech
Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under “Specialty drugs,” only to be available through specialty pharmacies (under FDA’s Risk Evaluation and Mitigation Strategy (REMS) program).
Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate, wherein no data demonstrate any improvement in disease-related symptoms or increased survival with Avastin.
Product details in the report…
Temodar/Temodal: Merck
The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine.
Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly.
Temodar/Temodal was initially commercialized by Merck in the different countries, whereas Baxter Oncology was responsible for the manufacture of Temodar injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of Temozolomide has also been approved by Double Bond Pharmaceuticals.
Product details in the report…
Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma.
Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depending on many factors like the size and location of the tumor; the extent to which the tumor has grown into the surrounding normal brain tissues; and the affected person’s age and overall health.
In April 2005, the FDA approved a new indication for Temodar capsules (temozolomide) for concurrent use with radiotherapy for the treatment of adults with newly diagnosed GBM and as maintenance therapy after radiotherapy. Inaddition, in December 2017, the FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. In case of European and Japanese market, only Temodar has been approved by the EMA and MHLW respectively, for the treatment of patients with GBM.
Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which is yet to be launched. The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.
The potential candidates with promising results in late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), and Regorafenib (Bayer).
Key Findings
This section includes a glimpse of the Glioblastoma Multiforme (GBM) 7MM market.
- The market size of GBM in the seven major markets was estimated to be USD 1,005 Million in 2017.
- The United States accounts for the largest market size of GBM throughout the study period of 2017–2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 629 Million in 2017.
- Among the EU5 countries, Germany had the highest market size with USD 73 Million in 2017, while Spain had the lowest market size with USD 35 Million.
- Japan accounted for the second highest market size in the 7 MM during the forecast period of 2020–2030, which was estimated to be USD 82 Million in 2017.
Request for sample pages @ Glioblastoma Multiforme Market
Table of contents
1. Key Insights
2. Glioblastoma Multiforme Market Overview at a Glance
2.1. Market Share (%) Distribution of GBM in 2017
2.2. Market Share (%) Distribution of GBM in 2030
3. Executive Summary of Glioblastoma Multiforme (GBM)
4. Disease Background and Overview: Glioblastoma Multiforme (GBM)
4.1. Introduction
4.2. Classification of Glioblastoma Multiforme
4.3. Glioblastoma Types
4.3.1. Astrocytomas
4.3.2. Ependymomas
4.3.3. Oligodendrogliomas
4.3.4. Mixed gliomas
4.3.5. Optic pathway gliomas
4.4. Symptoms
4.5. Pathophysiology
4.5.1. Macroscopic and Histological Features of GBM
4.5.2. Genetic and Molecular Pathogenesis
4.6. Inheritance of Glioblastoma Multiforme
4.6.1. Genetic Variations of Glioblastoma Multiforme
4.7. Molecular Classification
4.7.1. Specific Molecular Biomarkers
4.8. Diagnosis of Glioblastoma Multiforme
4.8.1. Neurological Exams
4.8.2. Angiograms
4.8.3. Magnetic resonance imaging (MRI) and computerized Tomography (CT)
4.8.4. Perfusion MRI
4.8.5. MR spectroscopy
4.8.6. Histological Diagnosis
4.8.7. Surgical Biopsy
4.9. Glioblastoma in Nut Shell
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Total Diagnosed Incident Patient Population of Glioblastoma Multiforme
6. Country Wise-Epidemiology of Glioblastoma Multiforme
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States
6.1.3. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
6.1.4. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
6.1.5. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
6.1.6. Diagnosed Incident Population based on Primary Site of GBM in the United States
6.1.7. Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany
6.3.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
6.3.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
6.3.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
6.3.5. Diagnosed Incident Population based on Primary Site of GBM in Germany
6.3.6. Diagnosed Incident Population based on Histologic Classification of GBM in Germany
6.4. France
6.4.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in France
6.4.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France
6.4.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France
6.4.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France
6.4.5. Diagnosed Incident Population based on Primary Site of GBM in France
6.4.6. Diagnosed Incident Population based on Histologic Classification of GBM in France
6.5. Italy
6.5.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy
6.5.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
6.5.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
6.5.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
6.5.5. Diagnosed Incident Population based on Primary Site of GBM in Italy
6.5.6. Diagnosed Incident Population based on Histologic Classification of GBM in Italy
6.6. Spain
6.6.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain
6.6.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
6.6.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
6.6.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
6.6.5. Diagnosed Incident Population based on Primary Site of GBM in Spain
6.6.6. Diagnosed Incident Population based on Histologic Classification of GBM in Spain
6.7. United Kingdom
6.7.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom
6.7.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
6.7.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
6.7.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
6.7.5. Diagnosed Incident Population based on Primary Site of GBM in the United Kingdom
6.7.6. Diagnosed Incident Population based on Histologic Classification of GBM in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan
6.8.3. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
6.8.4. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
6.8.5. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
6.8.6. Diagnosed Incident Population based on Primary Site of GBM in Japan
6.8.7. Diagnosed Incident Population based on Histologic Classification of GBM in Japan
7. Treatment
7.1. Surgery
7.2. Chemotherapy
7.3. Radiation
7.4. Others
7.4.1. Targeted therapy
7.4.2. Tumor treatment fields (TTF)
7.4.3. Immunotherapy
7.5 Management of Symptoms with Medication
8. Treatment Algorithm
9. The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma
10. The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma
11. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
11.1. Medical Management and Supportive Care
11.2. Standard Therapy
11.3. Surgical Management
11.4. Radiotherapy Considerations
11.5. Recurrent Glioblastoma Scenario
12. SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma
13. Recognized Establishments
14. Unmet Needs
15. Marketed Drugs
15.1. Avastin: Genentech
15.1.1. Drug Description
15.1.2. Regulatory Milestones
15.1.3. Other Development Activities
15.1.4. Safety and Efficacy
15.1.5. Product Profile
15.2. Temodar/Temodal: Merck
15.2.1. Drug Description
15.2.2. Regulatory Milestones
15.2.3. Other Development Activities
15.2.4. Safety and Efficacy
15.2.5. Product Profile
16. Emerging Drugs
16.1. Key Cross Competition
16.2. Other emerging therapies in development
16.3. Ofranergene obadenovec (VB-111): VBL Therapeutics
16.3.1. Product Description
16.3.2. Clinical Development
16.3.3. Safety and Efficacy
16.4. Trans Sodium Crocetinate: Diffusion Pharmaceuticals
16.4.1. Product Description
16.4.2. Clinical Development
16.4.3. Safety and Efficacy
16.5. Regorafenib: Bayer
16.5.1. Product Description
16.5.2. Clinical Development
16.5.3. Safety and Efficacy
16.6. Durvalumab (MEDI4736): MedImmune
16.6.1. Product Description
16.6.2. Clinical Development
16.6.3. Safety and Efficacy
16.7. Tasadenoturev (DNX-2401): DNAtrix
16.7.1. Product Description
16.7.2. Clinical Development
16.7.3. Safety and Efficacy
16.8. ONC201: Oncoceutics
16.8.1. Product Description
16.8.2. Clinical Development
16.8.3. Safety and Efficacy
16.9. Selinexor (KPT-330): Karyopharm Therapeutics
16.9.1. Product Description
16.9.2. Clinical Development
16.9.3. Safety and Efficacy
16.10. VBI-1901: VBI Vaccines
16.10.1. Product Description
16.10.2. Clinical Development
16.10.3. Safety and Efficacy
16.11. Paxalisib (GDC-0084): Kazia Therapeutics
16.11.1. Product Description
16.11.2. Clinical Development
16.11.3. Safety and Efficacy
16.12. AV-GBM-1: Aivita Biomedical
16.12.1. Product Description
16.12.2. Clinical Development
16.12.3. Safety and Efficacy
16.13. MDNA55: Medicenna Therapeutics
16.13.1. Product Description
16.13.2. Clinical Development
16.13.3. Safety and Efficacy
16.14. VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals
16.14.1. Product Description
16.14.2. Clinical Development
16.14.3. Safety and Efficacy
16.15. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
16.15.1. Product Description
16.15.2. Clinical Development
16.15.3. Safety and Efficacy
16.16. INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals
16.16.1. Product Description
16.16.2. Clinical Development
16.16.3. Safety and Efficacy
17. Glioblastoma Multiforme: 7 Major Market Analysis
17.1. Key Findings
17.2. Total Market Size of Glioblastoma Multiforme in the 7 MM
17.3. The United States Market Outlook
17.4. United States Market Size
17.4.1. Total Market size of Glioblastoma Multiforme in the United States
17.4.2. Market Size of Glioblastoma Multiforme by Current Therapies
17.4.3. Market Size of Glioblastoma Multiforme by Emerging Therapies
17.5. EU-5 Countries: Market Outlook
17.6. Germany
17.6.1. Total Market size of Glioblastoma Multiforme in Germany
17.6.2. Market Size of Glioblastoma Multiforme by Current Therapies
17.6.3. Market Size of Glioblastoma Multiforme by Emerging Therapies
17.7. France
17.7.1. Total Market Size of Glioblastoma Multiforme in France
17.7.2. Market Size of Glioblastoma Multiforme by Current Therapies
17.7.3. Market Size of Glioblastoma Multiforme by Emerging Therapies
17.8. Italy
17.8.1. Total Market Size of Glioblastoma Multiforme in Italy
17.8.2. Market Size of Glioblastoma Multiforme by Current Therapies
17.8.3. Market Size of Glioblastoma Multiforme by Emerging Therapies
17.9. Spain
17.9.1. Total Market Size of Glioblastoma Multiforme in Spain
17.9.2. Market Size of Glioblastoma Multiforme by Current Therapies
17.9.3. Market Size of Glioblastoma Multiforme by Emerging Therapies
17.1. United Kingdom
17.10.1. Total Market Size of Glioblastoma Multiforme in the United Kingdom
17.10.2. Market Size of Glioblastoma Multiforme by Current Therapies
17.10.3. Market Size of Glioblastoma Multiforme by Emerging Therapies
17.11. Japan: Market Outlook
17.11.1. Total Market Size of Glioblastoma Multiforme in Japan
17.11.2. Market Size of Glioblastoma Multiforme by Current Therapies
17.11.3. Market Size of Glioblastoma Multiforme by Emerging Therapies
18. Market Access and Reimbursement
18.1. United States
18.2. Europe
18.3. Japan
19. Case Reports
19.1. Glioblastoma and intracranial aneurysms: Case report and review of the literature (United States)
19.2. A New Method for Ethical and Efficient Evidence Generation for Off-label Medication Use in Oncology (A Case Study in Glioblastoma) (United Kingdom)
19.3. Diagnosis and treatment of early-stage glioblastoma (Japan)
20. KOL Reviews
21. Market Drivers
22. Market Barriers
23. SWOT Analysis
24. Appendix
24.1. Bibliography
24.2. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/